Opendata, web and dolomites

AuriGen SIGNED

Next Generation Left Atrial Appendage Implant to Treat Persistent Atrial Fibrillation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AuriGen project word cloud

Explore the words cloud of the AuriGen project. It provides you a very rough idea of what is the project "AuriGen" about.

device    entering    specialist    germany    fit    causing    expand    complete    incapable    time    human    classified    distributors    too    mechanically    redo    italy    surgical    amounting    approximately    france    procedure    stream    electrical    30    tissue    cardiac    financially    flow    filter    irregular    launch    market    international    electrically    atrial    enter    ce    first    patients    opportunity    heart    occlusion    commercial    isolation    works    shut    prevent    uk    blood    shot    isolates    rates    treatment    contraction    doubles    wasted    health    implant    stroke    clinical    approval    billion    surgery    implants    healthcare    destroys    72    doubled    permanently    therapy    risk    fitting    services    paf    opening    persistent    treating    clots    laa    invasive    5bn    fibrillation    left    appendage    least    arrhythmia    minimally    million    abnormal    af    markets    hours    heartbeat    pulses    13    muscle    caused    tier   

Project "AuriGen" data sheet

The following table provides information about the project.

Coordinator
AURIGEN MEDICAL LIMITED 

Organization address
address: 18 CHURCHWELL SQUARE
city: DUBLIN
postcode: DUBLIN 13
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.aurigenmedical.com
 Total cost 3˙503˙093 €
 EC max contribution 2˙452˙165 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AURIGEN MEDICAL LIMITED IE (DUBLIN) coordinator 2˙452˙165.00

Map

 Project objective

Atrial Fibrillation (AF) is an irregular heartbeat that can lead to blood clots, high risk of stroke and heart failure. AF is caused by abnormal electrical activity in the heart. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF). Surgical treatment for AF is a minimally invasive electrical therapy which destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients.

We have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. EU and US PAF represents a $5bn/yr market opportunity. We will enter the market directly in our target Tier 1 European markets (Germany, France, Italy and UK). We will scale using specialist distributors to expand into further European, US and other international markets.

In this Phase 2 we will complete the technical, pre-clinical and first in human clinical studies required to achieve CE approval in Europe as well as market development work for commercial launch.

 Deliverables

List of deliverables.
Sales Director Appointed Other 2019-11-25 12:36:59
Operations Director Appointed Other 2019-11-25 12:36:58

Take a look to the deliverables list in detail:  detailed list of AuriGen deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURIGEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURIGEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More  

Presque (2019)

Smart Nursing Bra

Read More